Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central nervous method, conolidine modulates alternate molecular targets. A Science Innovations research uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://charleso085dtl4.bloggosite.com/profile